DOJ shake-up could help advocates in abortion pill cases
EXCLUSIVE — Anti-abortion advocates are trying to take advantage of a change in leadership at the Department of Justice with a new effort to pressure the Trump administration to change course on several key cases involving the abortion pill mifepristone.

TL;DR
- Anti-abortion groups are pressuring the new acting Attorney General, Todd Blanche, to change the Department of Justice's stance on mifepristone cases.
- Approximately 80 anti-abortion organizations sent a letter asking the DOJ to support states suing the FDA over online prescriptions for abortion pills.
- The litigation concerns the FDA's 2023 decision to remove in-person screening requirements for mifepristone, allowing it to be mailed.
- States argue that mail-order mifepristone bypasses their laws banning elective abortions and prevents them from protecting citizens from coerced abortions.
- The Trump administration's DOJ previously sided with the FDA, stating states lack the legal standing to challenge drug safety decisions.
- The article highlights the case of Rosalie Markezich, who claims she was pressured into an abortion using pills obtained online without consulting a doctor.
- A Trump-appointed judge temporarily paused Louisiana's lawsuit against the FDA pending a safety review of mifepristone promised by FDA Commissioner Dr. Marty Makary and HHS Secretary Robert F. Kennedy Jr.
- Advocates suspect the safety review is being intentionally delayed until after the 2026 midterm elections.
- Susan B. Anthony Pro-Life America President Marjorie Dannefelser stated the DOJ has the opportunity to support states and protect women and unborn children from unregulated abortion drugs by mail.